USTR opens Section 301 investigation into Germany's

Cresthaven Analytics Intelligence Brief

Headline

USTR opens Section 301 investigation into Germany's pharmaceutical pricing practices with public hearing scheduled

Executive Summary

The Office of the United States Trade Representative initiated a Section 301 investigation on June 24, 2026 targeting Germany's pricing and reimbursement practices for innovative pharmaceutical products. The inter-agency Section 301 Committee is conducting a public hearing and accepting public comments as part of the investigation.

Bottom Line

The USTR's Section 301 initiation places Germany's AMNOG reimbursement framework inside a formal U.S. trade remedy proceeding, with tariffs and import restrictions among the authorized outcomes. Pharmaceutical manufacturers with products subject to German benefit assessments now operate within an active federal investigation whose record is open for submission. The investigation's structure as a template action, following a May 2026 executive directive, means the compliance and strategic exposure extends beyond Germany to every trading partner with analogous reference-pricing or reimbursement frameworks.

Key Regulatory Signals

Formal Investigation Opens Trade Remedy Pathway: The USTR's initiation of a Section 301 investigation places Germany's pharmaceutical reimbursement system under formal U.S. trade law scrutiny. If the investigation finds actionable practices, the USTR holds authority to recommend tariffs, import restrictions, or other trade measures against German goods or services.
Public Hearing Creates Formal Record: The inter-agency Section 301 Committee is conducting a public hearing, establishing an official evidentiary record. Pharmaceutical manufacturers, trade associations, and other interested parties with pricing or market-access exposure in Germany have a defined procedural window to submit comments and testimony.
Innovative Pharmaceutical Products Are the Defined Scope: The investigation is scoped to Germany's persistent underpayment for innovative pharmaceutical products, a reference to Germany's AMNOG framework, which sets reimbursement prices through benefit assessments that U.S. industry has characterized as systematically below market value. Companies with products subject to AMNOG negotiations carry direct exposure to the investigation's findings.
Retaliatory Measures Remain a Downstream Possibility: Section 301 investigations that conclude with a finding of unreasonable or discriminatory trade practices authorize the USTR to impose trade actions. German exporters and U.S. importers of German goods operate under the procedural posture that retaliatory measures are a defined outcome pathway, not a speculative one.
Broader Pharmaceutical Pricing Agenda Signals Sector-Wide Relevance: This investigation follows the May 2026 executive order directing the USTR to pursue Section 301 actions against countries with pharmaceutical pricing policies the administration characterizes as free-riding on U.S. innovation. Germany is the first named target; the investigation's structure and findings establish a template applicable to other trading partners.

Regulatory Delta

- No prior Section 301 action has targeted a single allied nation's domestic drug reimbursement framework. Earlier pharmaceutical-sector Section 301 actions addressed market-access barriers and intellectual property, not pricing levels.

- The investigation advances a novel legal theory: that a trading partner's domestic reimbursement price constitutes an actionable trade practice under U.S. trade law. This marks a structural departure from the established scope of Section 301.

- A May 2026 executive order directed USTR to pursue pharmaceutical pricing investigations against multiple trading partners, providing the executive predicate for this action and signaling that additional country-specific investigations will follow.

Materiality Classification

HIGH — The investigation opens a formal Section 301 trade remedy proceeding with tariff and import-restriction authority as defined outcomes; pharmaceutical manufacturers with German market exposure and importers of German goods must assess their procedural standing and comment-period participation, and the action's template framing extends sector-wide exposure beyond Germany.

Intelligence Outlook

Monitor the Federal Register and USTR press releases for the public hearing date, comment deadline, and any subsequent USTR determination or trade action recommendation under this investigation.